Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015677 | 0.91 | KDM4E (0.44) | GAAPOLBMAPTSMN1; SMN2LMNA | |
| SCHEMBL1013901 | 0.88 | MAPT (0.41) | RXFP1GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL1013863 | 0.88 | SERPINE1 (0.44) | RXFP1GAAPOLBMAPTLMNA | |
| SCHEMBL1014811 | 0.87 | ALDH1A1 (0.45) | RXFP1GAAPOLBMAPTSMN1; SMN2 | |
| SCHEMBL1015814 | 0.80 | LMNA (0.43) | RXFP1GAAPOLBMAPTSMN1; SMN2 | |
| SCHEMBL1012901 | 0.79 | RXFP1 (0.38) | RXFP1GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL1014871 | 0.79 | SERPINE1 (0.51) | GAAPOLBMAPTSMN1; SMN2TDP1 | |
| SCHEMBL1014912 | 0.79 | MEN1 (0.42) | RXFP1GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL1015634 | 0.76 | ALDH1A1 (0.53) | RXFP1GAAPOLBMAPTSMN1; SMN2 | |
| SCHEMBL1013719 | 0.76 | SERPINE1 (0.44) | RXFP1GAAPOLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | RXFP1 1415/4885GAA 459/4885POLB 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.